Included in the formulation
АТХ:A.02.B.X Other antiulcer drugs
Pharmacodynamics:Rebambid increases the content of prostaglandin E2 (PGE2) in the gastric mucosa and increases the content of PGE2 and GI2 in the contents of gastric juice. Has a cytoprotective effect against the gastric mucosa with damaging effects of ethanol, acids and alkalis, acetylsalicylic acidth acid. Promotes the activation of enzymes that accelerate biosynthesis of high molecular weightglycoproteins, and increases the mucus content on the surface of the stomach wall. It helps to improve the blood supply to the gastric mucosa, activates its barrier function, activates the alkaline secretion of the stomach, strengthens the proliferation and exchange of epithelial cells of the stomach, cleans mucosa from hydroxyl radicals and suppresses superoxide, produced polymorphonuclearleukocytes and neutrophils in the presence of Helicobacter pylori, protects the gastric mucosa from damage by bacteria, has a gastroprotectivethe effect of non-steroidal anti-inflammatory action on mucous membranes(NSAIDs)
Pharmacokinetics:Absorption when ingested - high. After taking in a dose of 100 mg, the maximum concentration is reached after approximately 2 hours and is 340 ng / ml.The half-life is approximately 1.0 h. Repeated drug administration does not lead to its cumulation in the body. Approximately 10% of the drug is excreted by the kidneys, mostly unchanged. When administered at a dose of 600 mg, it is possible to isolate traces of a hydroxylated metabolite.
In vitro experiments it was shown that from 98.4% to 98.6% of the drug is bound by plasma proteins.
Indications:- Stomach ulcer.
- Chronic gastritis with increased acid-forming function of the stomach in the stage of exacerbation, erosive gastritis.
- Prevention of mucosal lesions on the background of non-steroidal anti-inflammatory drugs.
- In the combination therapy.
XI.K20-K31.K25 Stomach ulcer
XI.K20-K31.K27 Peptic ulcer of unspecified site
XI.K20-K31.K29 Gastritis and duodenitis
Contraindications:- Individual intolerance to ribabipide or other components of the drug.
- Pregnancy, lactation.
- Children under the age of 18 years.
Carefully:At the first appointment of rebamipid patients from the elderly in connection with the possibility of the emergence of hypersensitivity to the drug.
Pregnancy and lactation:The safety of the use of rebamipide during pregnancy is not proven. Do not use during pregnancy. Because the rebamipide penetrates into breast milk, breastfeeding should be discontinued, or the issue of infant feeding should be resolved if a mother of rebamipid is to be given during breastfeeding.
Dosing and Administration:Inside 1 tablet 3 times a day, with a small amount of liquid. The course of treatment is 2-4 weeks, if necessary, can be extended to 8 weeks. The drug does not have the features of the action at the first reception or upon its cancellation. If you miss a dose, you need to take the next dose of the drug at the set time, do not take twice the dose of the drug.
Side effects:From the side gastrointestinal tract: constipation, flatulence, diarrhea, nausea, vomiting, pain in the abdomen, a violation of taste, heartburn.
From the side liver: signs of liver dysfunction, increased serum glutamine alanine aminotransferase (ALT) and serum glutamine aspartate aminotransferase (ACT).
From the side hematopoiesis system: leukopenia, granulocytopenia.
Allergic reactions: itching, skin rash, eczematous rashes.
Other: violation of the menstrual cycle.
Overdose:Symptoms of an overdose with rebamipide are not described, until today information about cases of deliberate overdose has not been reported. There may be nausea, vomiting, abdominal pain, diarrhea or constipation, headache.
Measures to assist: a specific antidote is unknown. In case of an overdose, wash the stomach and perform symptomatic therapy.
Interaction:With the use of rebamipide in the traditional regimens of therapy of patients with infection Helicobacter pylori, the effectiveness of eradication therapy significantly increases.
Reactions with other drugs have not been studied.
Special instructions:Impact on the ability to drive vehicles and manage mechanisms
The effect of the drug on the rate of psychomotor reactions and / or the ability to control vehicles or mechanisms has not been studied. In case of taking the drug should be cautious about driving the car and other activities that require increased concentration of attention.